286 related articles for article (PubMed ID: 21821523)
61. The "no-reflow" phenomenon after temporary coronary occlusion in the dog.
Kloner RA; Ganote CE; Jennings RB
J Clin Invest; 1974 Dec; 54(6):1496-508. PubMed ID: 4140198
[TBL] [Abstract][Full Text] [Related]
62. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion.
Zhao JL; Yang YJ; Cui CJ; You SJ; Wu YJ; Gao RL
Cardiovasc Drugs Ther; 2006 Jun; 20(3):167-75. PubMed ID: 16775665
[TBL] [Abstract][Full Text] [Related]
63. New and revisited approaches to preserving the reperfused myocardium.
Kloner RA; Brown DA; Csete M; Dai W; Downey JM; Gottlieb RA; Hale SL; Shi J
Nat Rev Cardiol; 2017 Nov; 14(11):679-693. PubMed ID: 28748958
[TBL] [Abstract][Full Text] [Related]
64. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion.
Reffelmann T; Hale SL; Li G; Kloner RA
Am J Physiol Heart Circ Physiol; 2002 Feb; 282(2):H766-72. PubMed ID: 11788428
[TBL] [Abstract][Full Text] [Related]
65. Assessment of microvascular injury after acute myocardial infarction: importance of the area at risk.
Klem I; Kim RJ
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):756-7. PubMed ID: 18852712
[TBL] [Abstract][Full Text] [Related]
66. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4.
Galaup A; Gomez E; Souktani R; Durand M; Cazes A; Monnot C; Teillon J; Le Jan S; Bouleti C; Briois G; Philippe J; Pons S; Martin V; Assaly R; Bonnin P; Ratajczak P; Janin A; Thurston G; Valenzuela DM; Murphy AJ; Yancopoulos GD; Tissier R; Berdeaux A; Ghaleh B; Germain S
Circulation; 2012 Jan; 125(1):140-9. PubMed ID: 22086875
[TBL] [Abstract][Full Text] [Related]
67. The challenges and impact of microvascular injury in ST-elevation myocardial infarction.
Reinstadler SJ; Stiermaier T; Fuernau G; de Waha S; Desch S; Metzler B; Thiele H; Eitel I
Expert Rev Cardiovasc Ther; 2016; 14(4):431-43. PubMed ID: 26794717
[TBL] [Abstract][Full Text] [Related]
68. Intramyocardial hemorrhage: an enigma for cardiac MRI?
Calvieri C; Masselli G; Monti R; Spreca M; Gualdi GF; Fedele F
Biomed Res Int; 2015; 2015():859073. PubMed ID: 25759823
[TBL] [Abstract][Full Text] [Related]
69. Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon.
Reffelmann T; Kloner RA
J Cardiovasc Pharmacol Ther; 2004 Sep; 9(3):163-72. PubMed ID: 15378136
[TBL] [Abstract][Full Text] [Related]
70. No-reflow: incidence and detection in the cath-lab.
Niccoli G; Cosentino N; Spaziani C; Fracassi F; Tarantini G; Crea F
Curr Pharm Des; 2013; 19(25):4564-75. PubMed ID: 23270553
[TBL] [Abstract][Full Text] [Related]
71. Update in pharmacological management of coronary no-reflow phenomenon.
Salinas P; Jimenez-Valero S; Moreno R; Sanchez-Recalde A; Galeote G; Calvo L; Ruiz-Garcia J; Carrizo S; Trucco G; Lopez-Sendon J
Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):256-64. PubMed ID: 22827250
[TBL] [Abstract][Full Text] [Related]
72. Relationship between retrograde coronary blood flow and the extent of no-reflow and infarct size in a porcine ischemia-reperfusion model.
Stavrakis S; Terrovitis J; Tsolakis E; Drakos S; Dalianis A; Bonios M; Koudoumas D; Malliaras K; Nanas J
J Cardiovasc Transl Res; 2011 Feb; 4(1):99-105. PubMed ID: 21153063
[TBL] [Abstract][Full Text] [Related]
73. Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2.
Long R; You Y; Li W; Jin N; Huang S; Li T; Liu K; Wang Z
Life Sci; 2015 Dec; 142():8-18. PubMed ID: 26482204
[TBL] [Abstract][Full Text] [Related]
74. Advances in Coronary No-Reflow Phenomenon-a Contemporary Review.
Karimianpour A; Maran A
Curr Atheroscler Rep; 2018 Jul; 20(9):44. PubMed ID: 29974260
[TBL] [Abstract][Full Text] [Related]
75. Prediction of the no-reflow phenomenon with ultrasonic tissue characterization in patients with anterior wall acute myocardial infarction.
Iwakura K; Ito H; Kawano S; Okamura A; Tanaka K; Nishida Y; Maekawa Y; Masuyama T; Hori M; Fujii K
Am J Cardiol; 2004 Jun; 93(11):1357-61, A5. PubMed ID: 15165914
[TBL] [Abstract][Full Text] [Related]
76. No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications.
Ito H
Acta Med Okayama; 2009 Aug; 63(4):161-8. PubMed ID: 19727200
[TBL] [Abstract][Full Text] [Related]
77. Calcium antagonists in myocardial ischemia/reperfusion--update 2012.
Kleinbongard P; Baars T; Heusch G
Wien Med Wochenschr; 2012 Jul; 162(13-14):302-10. PubMed ID: 22695811
[TBL] [Abstract][Full Text] [Related]
78. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit.
Reffelmann T; Kloner RA
Am J Physiol Heart Circ Physiol; 2002 Sep; 283(3):H1099-107. PubMed ID: 12181140
[TBL] [Abstract][Full Text] [Related]
79. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis.
Iwakura K; Ito H; Okamura A; Koyama Y; Date M; Higuchi Y; Inoue K; Kimura R; Nagai H; Imai M; Toyoshima Y; Ozawa M; Ito N; Okazaki Y; Shibuya M; Suenaga H; Kubota A; Fujii K
Circ J; 2009 May; 73(5):925-31. PubMed ID: 19325192
[TBL] [Abstract][Full Text] [Related]
80. The preventive effect of garlicin on a porcine model of myocardial infarction reperfusion no-reflow.
Li JH; Yang P; Li AL; Wang Y; Shi ZX; Ke YN; Li XL
Chin J Integr Med; 2014 Jun; 20(6):425-9. PubMed ID: 22539198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
